Terms: = Skin cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
554 results:
1. Efficiency and tolerance of second-line triple braf inhibitor/MEK inhibitor/anti-PD1 combined therapy in braf mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract] [Full Text] [Related]
2. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract] [Full Text] [Related]
3. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
4. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.
Kim HJ; Kim YH
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474231
[TBL] [Abstract] [Full Text] [Related]
6. Primary endobronchial melanoma: a case report and clinical management indications.
Barisione E; Boutros A; Mora M; Spagnolo F; Tanda ET; Genova C; Tagliabue E
BMC Pulm Med; 2024 Feb; 24(1):97. PubMed ID: 38402179
[TBL] [Abstract] [Full Text] [Related]
7. Alternative Wnt-signaling axis leads to a break of oncogene-induced senescence.
Kluge V; Kappelmann-Fenzl M; Fischer S; Zimmermann T; Pommer M; Kuphal S; Bosserhoff AK
Cell Death Dis; 2024 Feb; 15(2):166. PubMed ID: 38388496
[TBL] [Abstract] [Full Text] [Related]
8. Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance.
Dei Cas M; Ciniselli CM; Vergani E; Ciusani E; Aloisi M; Duroni V; Verderio P; Ghidoni R; Paroni R; Perego P; Beretta GL; Gatti L; Rodolfo M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338838
[TBL] [Abstract] [Full Text] [Related]
9. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update.
Roccuzzo G; Bongiovanni E; Tonella L; Pala V; Marchisio S; Ricci A; Senetta R; Bertero L; Ribero S; Berrino E; Marchiò C; Sapino A; Quaglino P; Cassoni P
Expert Rev Mol Diagn; 2024; 24(1-2):49-66. PubMed ID: 38334382
[TBL] [Abstract] [Full Text] [Related]
10. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Falcone R; Verkhovskaia S; Di Pietro FR; Poti G; Samela T; Carbone ML; Morelli MF; Zappalà AR; di Rocco ZC; Morese R; Piesco G; Marchetti P; Failla CM; De Galitiis F
Curr Oncol; 2024 Jan; 31(1):588-597. PubMed ID: 38275835
[TBL] [Abstract] [Full Text] [Related]
11. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M; Lorigan P; Sergi MC; Benannoune N; Serra P; Vitale MG; Giannarelli D; Arance AM; Couselo EM; Neyns B; Tucci M; Guida M; Spagnolo F; Rossi E; Occelli M; Queirolo P; Quaglino P; Depenni R; Merelli B; Placzke J; Di Giacomo AM; Del Vecchio M; Indini A; da Silva IP; Menzies AM; Long GV; Robert C; Rutkowski P; Ascierto PA
Eur J Cancer; 2024 Mar; 199():113542. PubMed ID: 38266540
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and predictive biomarkers in melanoma.
Maher NG; Vergara IA; Long GV; Scolyer RA
Pathology; 2024 Mar; 56(2):259-273. PubMed ID: 38245478
[TBL] [Abstract] [Full Text] [Related]
13. Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma.
Chen W; He Y; Zhou G; Chen X; Ye Y; Zhang G; Liu H
BMC Med; 2024 Jan; 22(1):24. PubMed ID: 38229080
[TBL] [Abstract] [Full Text] [Related]
14. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.
Sherman WJ; Romiti E; Michaelides L; Moniz-Garcia D; Chaichana KL; Quiñones-Hinojosa A; Porter AB
Curr Treat Options Oncol; 2023 Dec; 24(12):1962-1977. PubMed ID: 38158477
[TBL] [Abstract] [Full Text] [Related]
15. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract] [Full Text] [Related]
16. Local treatment of liver metastasis in a patient with advanced malignant melanoma: A case report.
Hong H; Shen L; Tan H; Wu Y; Liu Y; Fan W
J Cancer Res Ther; 2023 Dec; 19(6):1675-1679. PubMed ID: 38156937
[TBL] [Abstract] [Full Text] [Related]
17. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Louveau B; Reger De Moura C; Jouenne F; Sadoux A; Allayous C; Da Meda L; Bernard-Cacciarella M; Baroudjian B; Lebbé C; Mourah S; Dumaz N
Melanoma Res; 2024 Apr; 34(2):186-192. PubMed ID: 38141200
[TBL] [Abstract] [Full Text] [Related]
18. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract] [Full Text] [Related]
19. Demyelinating polyradiculoneuropathy during dabrafenib and trametinib treatment for metastatic melanoma: A case report.
Venturelli M; Greco S; Baldessari C; Pugliese G; Depenni R; Dominici M
Tumori; 2023 Dec; 109(6):NP21-NP26. PubMed ID: 38050794
[TBL] [Abstract] [Full Text] [Related]
20. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract] [Full Text] [Related]
[Next]
